As with any prescription medication, weekly semaglutide (GLP-1) injections for weight loss can cause side effects
Patrick Kee, MD, PhD, a cardiologist at Vital Heart & Vein, who was not involved in the study, noted the following about the studys results: The investigators demonstrated that the therapeutic efficacy of semaglutide on the primary cardiovascular composite endpoint indeed emerged early and persisted over the initial three months (hazard ratio [HR] 0.63, 95% confidence interval [CI] 0.41-0.95) and the subsequent six months (HR 0.60, 95% CI 0.44-0.81). While the underlying mechanisms of semaglutides early clinical benefits remain under investigation, these findings suggest an encouraging intervention capable of altering the trajectory of [patients with obesity] with established cardiovascular disease but without a diagnosis of diabetes, he told Medical News Today
Why weight regain happens Obesity is recognized as a chronic, relapsing condition not a failure of willpower
Costs and insurance factors also play a role in the decision, as coverage for weight-loss reasons is often uneven, leading to significant differences in out-of-pocket monthly expenses
